Nile Therapeutics Inc.
This article was originally published in Start Up
Executive Summary
For patients with acute decompensated heart failure, Nile Therapeutics is developing a drug related to known natriuretic peptides, which addresses three important mechanisms. CD-NP shows promise in fluid unloading, but without the side effect of low blood pressure that often accompanies other medications; it as the potential to reduce filling pressure; and it may also preserve, or possibly enhance, renal function.
You may also be interested in...
Start-Up Previews (10/2007)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Cardiovascular Drug Start-Ups," features profiles of AcelleRX Therapeutics, BioVascular, Nile Therapeutics and VIA Pharmaceuticals. Plus these Start-Ups Across Health Care: JenaValve, Moberg Derma, ProtAffin, and Virtual Ports.
Cardiovascular Drug Start-Ups
The cardiovascular drug marketplace has the dubious distinction of being the largest therapeutic category in terms of revenue, unmet need and mortality, while at the same time being the only area experiencing decreasing growth. Revenues will start to plummet starting in 2012 when the world's two largest CV drugs--Lipitor and Plavix--go generic. To help pharmas replace these and other aging drugs in their pipelines, Windhover's Therapeutic Alliances conference presents the "top 10" unpartnered clinical-stage cardiovascular programs.
Start-Up Previews (10/2007)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Cardiovascular Drug Start-Ups," features profiles of AcelleRX Therapeutics, BioVascular, Nile Therapeutics and VIA Pharmaceuticals. Plus these Start-Ups Across Health Care: JenaValve, Moberg Derma, ProtAffin, and Virtual Ports.